{"filings":[{"id":2393276,"accession_number":"0001193125-26-360081","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2026-08-21T13:20:55+00:00","items":["5.02","8.01"],"status":"ready","headline":"Waters announces resignation of SVP Analytical Sciences; Tina Wu to succeed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert L. Carpio III resigns as SVP, Waters Analytical Sciences Division, effective Aug 20, 2026, to pursue other opportunities.","Tina Wu, current SVP Materials Sciences and President China, will assume role of SVP Analytical Sciences.","Wu joined Waters in June 2026 after 20+ years at DuPont, most recently Global VP, President of DuPont Mobility & Materials since 2021.","Wu led DuPont businesses with annual net sales of $1B–$2.3B during her tenure there."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2033077,"accession_number":"0001193125-26-331413","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2026-08-04T10:10:22+00:00","items":["2.02","9.01"],"status":"ready","headline":"Waters Q2 revenue $1.645B beats guidance; raises full-year EPS and revenue outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $1.645B; organic revenue $828M (+9% constant currency) and acquired business revenue $817M.","GAAP diluted loss per share ($1.39); adjusted EPS $3.05, up 3% YoY and at high end of guidance.","ASD instrument growth 8% constant currency; Pharma and A&G end markets low-double-digit growth.","Full-year 2026 guidance raised: organic constant currency growth 7-9%, adjusted EPS $14.45-$14.65 (10-12% growth).","Q3 2026 guidance: organic constant currency growth 8-10%, adjusted EPS $3.95-$4.05 (16-19% YoY growth)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":609763,"accession_number":"0001193125-26-236929","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2026-05-22T20:15:20+00:00","items":["5.07"],"status":"ready","headline":"Waters shareholders re-elect all 11 directors, ratify PwC, approve say-on-pay at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Approx. 90.7M shares (92.4% of eligible) voted at May 21, 2026 annual meeting.","All 11 directors re-elected; Flemming Ornskov received 83.1M for, 3.96M against.","Ratification of PwC as auditor for FY 2026 passed with 84.8M for, 4.98M against.","Non-binding advisory vote on executive compensation approved 76.6M for, 10.7M against.","Votes on each proposal included broker non-votes totaling 3.39M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90493,"accession_number":"0001193125-26-204955","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Waters Q1 revenue $1.267B beats guidance; raises FY2026 adjusted EPS outlook to $14.40-$14.60","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total reported revenue of $1.267B exceeded guidance by $56M; GAAP EPS ($0.87) due to acquisition charges, Adjusted EPS $2.70 (+20% YoY).","Organic revenue grew 13% (11% constant currency), exceeding high end of guidance; driven by instrument and chemistry growth.","Acquired Biosciences & Diagnostic Solutions contributed $520M revenue from Feb 9 close, $40M above guidance.","Raising FY2026 organic constant currency growth guidance to 6.5%-8.0%, adjusted EPS to $14.40-$14.60.","Q2 2026 guidance: revenue $1.616B-$1.631B, adjusted EPS $2.95-$3.05."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":1267000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100045,"accession_number":"0001193125-26-119753","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Waters subsidiary issues $3.5B in senior notes across five tranches to repay DDTL","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issuer Augusta SpinCo completed offering of $3.5B senior notes: 4.321% due 2027, 4.398% 2029, 4.656% 2031, 4.945% 2033, 5.245% 2036.","Notes are fully and unconditionally guaranteed by Waters Corp and certain subsidiaries.","Proceeds used to repay $3.5B of indebtedness under delayed draw term loan incurred in February 2026.","Change of control triggers mandatory repurchase at 101% of principal plus accrued interest.","Underwriters include Barclays, Citigroup, J.P. Morgan, BofA Securities, and HSBC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100044,"accession_number":"0001193125-26-107339","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Waters provides financials for acquired BD Biosciences & Diagnostic Solutions; Q1 rev $766M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition closed Feb 9, 2026 via Reverse Morris Trust; Waters paid $4B cash distribution to BD.","BDS Business Q1 FY2026 net sales $766M (down 8% YoY from $834M); net income $49M vs $78M.","Operating income fell to $35M from $94M; includes $4M integration, restructuring & transaction costs.","Pro forma condensed combined financials as of Dec 31, 2025 and for FY2025 filed as Exhibit 99.4.","MD&A for fiscal years 2023-2025 and Q1 FY2026 provided; historical allocations may not reflect stand-alone costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100043,"accession_number":"0001193125-26-042819","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2026-02-09T23:59:59+00:00","items":["1.01","2.01","2.03","5.02","7.01","9.01"],"status":"ready","headline":"Waters completes $4B combination with BD's Biosciences & Diagnostic Solutions; forms four divisions","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Consummated spin-off and merger of BD's Biosciences & Diagnostic Solutions; BD shareholders received ~0.135 Waters shares per BD share, owning 39.2% of combined company.","SpinCo borrowed $4.0B term loan to fund cash payment to BD; Waters guaranteed the debt.","Claire M. Fraser, Ph.D. appointed to Waters Board, increasing size to 11.","New structure: four divisions - Analytical Sciences, Biosciences, Advanced Diagnostics, Materials Sciences.","Combined entity focused on high-volume testing in regulated applications; expects long-term value creation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100042,"accession_number":"0001193125-26-041897","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2026-02-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Waters Q4 2025 sales $932M (+7%), non-GAAP EPS $4.53 (+10%); BD deal closed; guides FY26 rev $6.4-6.5B, EPS $14.30-14.50","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 sales $932M (+7% reported, +6% CC); GAAP EPS $3.77, non-GAAP EPS $4.53 (+10% YoY).","Q4 end-markets: Pharma +8%, Industrial +8%, Academic/Gov -2%; Instruments +3%, Recurring +10% (Chemistry +12% CC).","Full-year 2025 sales $3,165M (+7%); non-GAAP EPS $13.13 (+11% YoY).","Closes BD Biosciences & Diagnostic Solutions acquisition; acquired business adds ~$3.0B revenue in FY2026.","FY2026 guidance: organic CC growth 5.5%-7.0%, total rev $6.405B-$6.455B; non-GAAP EPS $14.30-$14.50 (+8.9%-10.4% YoY)."],"consensus_eps_estimate":null,"consensus_eps_actual":10.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":3165286000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100041,"accession_number":"0001193125-26-024492","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2026-01-27T23:59:59+00:00","items":["5.07","7.01","8.01","9.01"],"status":"ready","headline":"Waters shareholders approve BD Biosciences combination; close expected Feb 9, 2026","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Approximately 99% of shares present at special meeting voted to approve share issuance for BD Biosciences deal.","Transaction expected to close on February 9, 2026, subject to remaining customary conditions.","IRS private letter ruling on tax consequences received; all required regulatory approvals secured.","Waters Q4 2025 earnings release and conference call rescheduled to February 9, 2026, in conjunction with close."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100040,"accession_number":"0001193125-26-015384","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2026-01-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Waters supplements merger proxy after two stockholder lawsuits alleging omissions","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Two lawsuits filed in NY Supreme Court (Carroll, Clark) claim proxy omits material information; demand letters also received.","Waters voluntarily adds multi-year financial projections (2025-2034) for standalone, advocacy, and SpinCo cases.","Barclays DCF analysis values Waters standalone at $20.9B-$24.7B equity range ($348-$411/share) using 9%-10% discount rate.","BDS Business enterprise value estimated at $16.8B-$19.7B standalone, $19.6B-$23.1B with synergies.","Special meeting of Waters stockholders to vote on merger remains January 27, 2026; Board continues recommendation FOR."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100039,"accession_number":"0001193125-26-010633","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Waters furnishes investor presentation at J.P. Morgan Conference; no financial details in excerpt","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filing furnishes investor presentation dated January 12, 2026 for J.P. Morgan Healthcare Conference.","Presentation cover indicates CEO Udit Batra presenting; content not included in filing excerpt.","Ongoing transaction with BD (spin-off of SpinCo) referenced; no new transaction details provided.","Form S-4 and definitive proxy previously filed and effective December 2025.","Unable to extract specific financial or operational updates from incomplete exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116386,"accession_number":"0001193125-25-263520","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Waters Q3 sales $800M (+8% YoY), non-GAAP EPS $3.40 (+16%), raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Sales $800M, +8% as reported and constant currency, above guidance.","GAAP EPS $2.50; non-GAAP EPS $3.40, up 16% YoY, above guidance.","Pharma +11% cc; instruments +6%, recurring +9% cc; chemistry double-digit growth.","FY25 constant currency sales growth guidance raised to +6.7% to +7.3%; non-GAAP EPS raised to $13.05-$13.15.","Integration planning for BD Biosciences acquisition progressing; CEO confident in synergies."],"consensus_eps_estimate":null,"consensus_eps_actual":2.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":799887000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132831,"accession_number":"0001193125-25-172076","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Waters Q2 sales $771M (+9% reported, +8% CC); GAAP EPS $2.47, non-GAAP $2.95; raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Sales $771M, up 9% reported and 8% constant currency vs $709M prior year.","GAAP EPS $2.47; non-GAAP EPS $2.95, up 12% YoY, above guidance mid-point.","Pharma segment grew 11% CC; Industrial +6%; Academic/Government declined 3%.","Raising FY2025 constant currency sales growth guidance to +5.5% to +7.5%; non-GAAP EPS $12.95-$13.05.","Q3 2025 guidance: constant currency sales growth +5.0% to +7.0%; non-GAAP EPS $3.15-$3.25."],"consensus_eps_estimate":null,"consensus_eps_actual":2.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":771332000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132830,"accession_number":"0001193125-25-158796","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2025-07-14T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Waters to acquire BD's Biosciences & Diagnostic Solutions via Reverse Morris Trust","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Waters shareholders to own ~60.8% and former SpinCo shareholders ~39.2% of combined company post-merger.","SpinCo will pay BD $4.0B cash prior to distribution; Waters arranged $1.8B bridge loan for potential special dividend.","Transaction unanimously approved by both boards; expected close by July 13, 2026, subject to regulatory and shareholder approvals.","Waters to pay BD $733M termination fee under certain circumstances if deal fails.","Post-closing board will have 11-12 members, with 1-2 appointed by BD after consultation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132829,"accession_number":"0001193125-25-158409","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2025-07-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Waters to combine with BD's Biosciences & Diagnostic Solutions in $17.5B deal","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Deal valued at ~$17.5B; Waters shareholders own ~60.8%, BD shareholders ~39.2% of combined co.","Pro forma 2025 revenue ~$6.5B, adjusted EBITDA ~$2.0B; expected accretive to adj EPS in Y1.","Targets mid-to-high single-digit revenue growth and mid-teens adj EPS growth annually 2025-2030.","Anticipates ~$345M annualized EBITDA synergies by 2030: $200M cost by Y3, $290M revenue by Y5.","Closing expected around end of Q1 2026, subject to regulatory approvals and Waters shareholder vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149385,"accession_number":"0001193125-25-130641","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Waters Corp amends credit facility; removes $200M term loan, retains $1.8B revolver through 2030","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Removed existing $200M term loan; retained $1.8B senior unsecured revolving credit facility maturing May 22, 2030.","May request up to $750M incremental commitments (total cap $2.55B); up to $50M available for letters of credit.","Interest spreads: Term SOFR + 80–112.5 bps; facility fee 7.5–22.5 bps based on leverage or debt ratings.","Leverage covenant max 3.50x (can rise to 4.25x for acquisitions ≥$500M cash consideration).","JPMorgan Chase remains administrative agent; subsidiaries guarantee obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149384,"accession_number":"0001193125-25-125877","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Waters Corp annual meeting elects all 10 directors, approves compensation and ESPP amendment","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Approximately 94.12% of shares represented; all 10 director nominees re-elected.","Ratification of PwC as auditor for fiscal 2025 approved (51.7M for vs 3.4M against).","Non-binding advisory vote on executive compensation passed (44.7M for, 9.6M against).","Amended and Restated 2009 Employee Stock Purchase Plan approved (54.3M for).","Broker non-votes of ~1.65M recorded on director election and advisory compensation votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149383,"accession_number":"0001193125-25-113232","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Waters Q1 2025 results announced; financial details not disclosed in excerpt","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Quarter ended March 29, 2025 results released May 6, 2025.","Press release furnished as Exhibit 99.1 but full text not available.","Investor contact: Caspar Tudor, Head of IR.","No specific revenue, EPS, or segment data provided."],"consensus_eps_estimate":4.5523,"consensus_eps_actual":2.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":662000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168450,"accession_number":"0001193125-25-024730","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Waters Q4 sales $873M beat guidance; non-GAAP EPS $4.10 up 13% YoY; FY2025 EPS guide $12.70-$13.00","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 sales $873M, +6% reported / +8% constant currency; exceeded high-end of guidance range.","Non-GAAP EPS $4.10 (+13% YoY); GAAP EPS $3.88; FX headwind ~9% in Q4.","Full-year sales $2,958M (flat); non-GAAP EPS $11.86 (+1%); operating cash flow $762M; free cash flow $744M (25% of sales).","FY2025 guidance: constant currency sales growth +4.5%–7.0%; non-GAAP EPS $12.70–$13.00; Q1 non-GAAP EPS $2.17–$2.25.","Pharma sales +10% constant currency; instruments +8%, recurring +9% constant currency in Q4."],"consensus_eps_estimate":null,"consensus_eps_actual":10.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":2958387000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168449,"accession_number":"0001193125-25-005378","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Waters to present at J.P. Morgan Healthcare Conference on Jan 13, 2025","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["CEO Udit Batra will present at the J.P. Morgan 43rd Annual Healthcare Conference on January 13, 2025.","Presentation includes high-level commentary on business performance, no detailed financial results disclosed.","Transcript will be available on Waters website in the Investors section under Events & Presentations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185580,"accession_number":"0001193125-24-249066","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2024-11-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Waters Q3 sales $740M (+4% YoY); GAAP EPS $2.71, non-GAAP $2.93; raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Sales $740M (+4% as reported and constant currency); GAAP EPS $2.71, non-GAAP EPS $2.93, beating guidance.","Instrument system sales returned to growth (+1%); recurring revenues up 6% as reported (7% constant currency).","FY 2024 organic constant currency sales growth guidance raised to -0.9% to -0.3%; non-GAAP EPS raised to $11.67-$11.87.","Q4 2024 guidance: constant currency sales growth +5% to +7%; non-GAAP EPS $3.90-$4.10."],"consensus_eps_estimate":null,"consensus_eps_actual":2.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":740305000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185579,"accession_number":"0001193125-24-249455","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K/A","filed_at":"2024-11-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Waters appoints Heather Knight to Nominating and Corporate Governance Committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Heather Knight was appointed to the Board effective August 14, 2024 per prior 8-K.","On October 31, 2024, the Board named Knight to the Nominating and Corporate Governance Committee, effective immediately.","The committee appointment is a routine governance update with no financial impact."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202158,"accession_number":"0001193125-24-200650","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Waters Corporation appoints Heather Knight to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Heather Knight effective Aug 14, 2024; Board size increased from 9 to 10.","Knight is EVP and Group President, Medical Products and Therapies at Baxter International.","Initial equity grant valued at $91,666 (50% RSU, 50% option), vesting on first anniversary.","Prorated cash retainer of $54,130 until 2025 AGM; standard non-employee director compensation.","Knight brings nearly three decades of global pharma and med device leadership experience."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202157,"accession_number":"0001193125-24-189455","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Waters reports Q2 2024 results; full financial details unavailable from excerpt","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release announces results for the quarter ended June 29, 2024, but full text is not provided.","No specific revenue, EPS, or segment figures can be extracted from the submitted text.","Investors should consult the complete press release for material financial information."],"consensus_eps_estimate":null,"consensus_eps_actual":2.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":708529000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202156,"accession_number":"0001193125-24-180722","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2024-07-18T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Waters Corp enters $200M private shelf note facility with NYL Investors","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Up to $200M senior promissory notes; maturity up to 15 years per issuance.","Proceeds for general corporate purposes: refinancing, share repurchases, capex, acquisitions.","Financial covenants: max leverage ratio 3.50:1.00, min interest coverage 3.50:1.00.","Shelf facility with no commitment; NYL may decline purchases; issuance period through Feb 2026.","Guaranteed by certain subsidiaries under a Guarantee Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218214,"accession_number":"0001193125-24-147025","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Waters shareholders elect all 9 directors, ratify PwC, approve say-on-pay and officer exculpation amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Quorum of 54.3M shares (91.63%) present; all 9 director nominees elected with votes ranging from 41.8M to 52.4M for.","Ratification of PricewaterhouseCoopers as auditor for FY2024 approved: 50.4M for, 3.9M against.","Non-binding advisory vote on named executive officer compensation passed: 42.0M for, 10.7M against.","Amendment to certificate of incorporation for officer exculpation under Delaware law approved: 48.7M for, 3.9M against.","Director Flemming Ornskov received the lowest support: 41.8M for, 9.7M against, 1.1M abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218213,"accession_number":"0001193125-24-132549","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Waters Corp reports Q1 2024 results; press release text truncated, no specifics available","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Company announced Q1 2024 results on May 7, 2024, but the attached press release text is incomplete.","Quarter ended March 30, 2024; key financial data (revenue, EPS) not included in provided document.","Further details are expected in the full press release referenced as Exhibit 99.1."],"consensus_eps_estimate":null,"consensus_eps_actual":1.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":636839000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238184,"accession_number":"0001193125-24-024758","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2024-02-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Waters Q4 2023 sales $819M (-4.5%); FY guidance organic growth -0.5% to +1.5%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP EPS $3.65, non-GAAP $3.62 (at high end of guidance); YoY decline from $3.84.","Full-year 2023 sales $2,956M (-0.5% as reported); non-GAAP EPS $11.75 vs $12.02 prior year.","Gross margin expanded 160bps to 59.6%; adjusted operating margin expanded 70bps to 30.9%.","China Q4 sales declined almost 40%; pharma sales down 6% as reported.","Q1 2024 guidance: organic sales -11% to -9%; non-GAAP EPS $2.05-$2.15."],"consensus_eps_estimate":null,"consensus_eps_actual":10.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":2956416000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238183,"accession_number":"0001193125-24-004832","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2024-01-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Waters provides J.P. Morgan conference deck; no detailed financials in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["CEO Udit Batra presented at J.P. Morgan 42nd Annual Healthcare Conference on January 8, 2024.","Presentation includes high-level commentary on business performance but full content not reproduced in filing.","Full presentation and transcript available on Waters' investor relations website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255642,"accession_number":"0001193125-23-271901","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Waters announces Q3 2023 results; details missing from filing excerpt","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Waters Corporation reported results for quarter ended Sep 30, 2023 on Nov 7, 2023.","Press release attached as Exhibit 99.1 but exhibit text is incomplete in provided filing.","No specific revenue, EPS, or segment data can be extracted from the available text."],"consensus_eps_estimate":null,"consensus_eps_actual":7.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":2136942000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255641,"accession_number":"0001193125-23-261216","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2023-10-24T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Waters Corp: SVP Jonathan Pratt resigns; Christos Ross named interim successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jonathan Pratt resigns as SVP of Waters Division effective Oct 24 to pursue external opportunity.","Christos Ross appointed Interim SVP of Waters Division, also continues as SVP of Global Operations.","Company initiates search for permanent successor, considering internal and external candidates.","Pratt will remain until Oct 27 to ensure smooth transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273088,"accession_number":"0001193125-23-201110","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2023-08-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Waters Q2 sales up 4% to $741M, non-GAAP EPS $2.80; lowers FY organic growth guide to 0.5-1.5%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Pharmaceutical market sales down 4% organic CC; China sales declined high teens.","Industrial +11% organic CC; Academic & Government +21% organic CC.","Full-year 2023 organic CC growth guided 0.5-1.5% (vs. prior); Q3 organic CC growth seen -4% to -2%.","Wyatt acquisition contributed 2% to Q2 sales; full-year impact ~2.5%.","Gross margin expanded 230 bps; non-GAAP EPS $2.80 vs. $2.75 a year ago."],"consensus_eps_estimate":null,"consensus_eps_actual":4.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":1425250000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289937,"accession_number":"0001193125-23-153040","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2023-05-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Waters re-elects all 9 directors, ratifies PwC, and approves say-on-pay at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 9 director nominees re-elected; votes ranged from 42.1M (Ornskov) to 49.7M (Batra, Brennan) for.","Ratification of PricewaterhouseCoopers as auditor approved: 50.3M for, 3.1M against, 41.9K abstain.","Non-binding say-on-pay proposal adopted with 40.1M for, 10.0M against, 53K abstain (3.3M broker non-votes).","Stockholders chose 1-year frequency for future say-on-pay votes (49.5M for 1 yr vs 549K for 3 yr)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289936,"accession_number":"0001193125-23-146126","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2023-05-16T23:59:59+00:00","items":["2.01","7.01","9.01"],"status":"ready","headline":"Waters completes $1.36B cash acquisition of Wyatt Technology","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total purchase price of $1.36B in cash, financed via balance sheet and credit facility.","Wyatt Technology generates >80% revenue from large molecule applications, accelerating Waters' bioanalytical business.","Deal expected to be accretive to adjusted EPS from Q1 2024; >$70M annual revenue synergies by year five.","Addressable market for cell/gene therapies projected at $1.8B with 10-12% annual growth.","Transaction expected immediately accretive to revenue growth and margin profile."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289935,"accession_number":"0001193125-23-142113","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Waters Corp issues $100M in 4.91% senior notes; establishes $400M private shelf facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $50M Series P 4.91% notes due 2028 and $50M Series Q 4.91% notes due 2030 to PGIM and purchasers.","Multi-currency private shelf facility allows up to $400M total notes outstanding, including existing $122M in other series.","Proceeds for general corporate purposes including debt repayment, share repurchases, capex, and acquisitions.","Covenants include leverage ratio ≤3.50:1.00 and interest coverage ratio ≥3.50:1.00.","Shelf notes can be issued in USD, EUR, or GBP; issuance period ends three years from signing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289934,"accession_number":"0001193125-23-138873","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Waters Q1 sales down 1% to $685M, non-GAAP EPS $2.49; guides FY organic growth 3-5%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 sales $685M (-1% reported, +3% constant currency); GAAP EPS $2.38, non-GAAP EPS $2.49, both down YoY.","Pharma sales -4% constant currency; recurring revenues +8% constant currency driven by service and chemistries.","FY2023 guidance: organic constant currency growth 3-5%; non-GAAP EPS $12.55-$12.75, including ~1% FX headwind.","Q2 2023 guidance: organic CC growth 1-3%; non-GAAP EPS $2.52-$2.62, with ~1% FX and ~3% Wyatt dilution.","Pending Wyatt Technology acquisition expected to close Q2 2023, adding ~2.5% to FY reported sales; accretive Q1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":2.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":684674000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310895,"accession_number":"0001193125-23-081472","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2023-03-28T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Waters appoints Richard Fearon (ex-Eaton VP/CFO) to Board; size increased to 10","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Richard Fearon appointed effective March 27, 2023, filling a new vacancy; Board expanded from 9 to 10 members.","Fearon will serve on Audit Committee; receives standard non-employee director compensation plus initial equity grant of $183,333.","Prorated cash retainer of $10,972 for service until 2023 annual meeting; board meeting fees also apply.","Edward Conard, director since 1994, will retire at the 2023 Annual Meeting; after that Board returns to 9 members."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310894,"accession_number":"0001193125-23-062099","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2023-03-07T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Waters Corp increases revolving credit facility by $200M to $2.0B, transitions to Term SOFR","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Revolving facility increased by $200 million to aggregate $2.0 billion.","LIBOR replaced with Term SOFR as benchmark rate under the amended credit agreement.","Amendment effective March 3, 2023; 14 lenders provided incremental commitments.","Existing credit agreement terms otherwise unchanged; subsidiary guarantees reaffirmed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310893,"accession_number":"0001193125-23-039737","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2023-02-15T23:59:59+00:00","items":["1.01","2.02","7.01","9.01"],"status":"ready","headline":"Waters to acquire Wyatt Technology for $1.36B cash; Q4 revenue up 9% CC, EPS beat","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition of Wyatt Technology for $1.36B cash, expected to close Q2 2023.","Wyatt had ~$110M 2022 revenue, 20% 3-year CAGR, ~40% adjusted operating margin.","Transaction accretive to non-GAAP EPS starting Q1 2024; >$70M annual revenue synergies by year 5.","Q4 2022 sales $859M (+9% CC); GAAP EPS $3.81, non-GAAP $3.84.","FY2023 guidance: organic CC growth 5-6.5%, non-GAAP EPS $12.55-$12.75."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310892,"accession_number":"0001193125-23-004869","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Waters presents at J.P. Morgan Healthcare Conference; no specific financial updates in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["CEO Udit Batra presented at J.P. Morgan 41st Annual Healthcare Conference on Jan 9, 2023.","Presentation slide filed as Exhibit 99.1 contains only title slide; no performance data disclosed.","Company stated high-level commentary on business performance would occur during session.","No material financial or operational updates provided in the 8-K or exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329502,"accession_number":"0001193125-22-304473","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K/A","filed_at":"2022-12-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Waters Corp assigns new directors to Audit and Nominating committees","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dan Brennan appointed to Audit Committee effective December 13, 2022.","Mark Vergnano appointed to Nominating and Corporate Governance Committee effective same date.","Appointments follow board entry on November 23, 2022; amendment filed December 14, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329504,"accession_number":"0001193125-22-291639","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2022-11-23T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Waters Corp appoints Dan Brennan and Mark Vergnano to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 7 to 9 members; appointments effective November 23, 2022.","Brennan is EVP & CFO of Boston Scientific; Vergnano is former Chairman, President & CEO of Chemours.","Each receives initial equity grant valued at $36,666 (50% RSU, 50% NSO) vesting in one year, plus prorated cash retainer of $7,418.","Both deemed independent under NYSE standards; board now 8 of 9 independent, 5 appointed in last 5 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329503,"accession_number":"0001193125-22-274470","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2022-11-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Waters Q3 sales $709M (+7% reported, +15% cc); raises FY22 sales guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS $2.60 flat YoY; non-GAAP EPS $2.64 vs $2.66 (FX headwind ~13%).","Instrument sales +21% cc; recurring revenues +10% cc; all major geographies double-digit cc.","Raised FY22 constant currency sales growth guidance to 11.5%-12%.","Updated FY22 non-GAAP EPS guidance to $11.85-$11.95, including ~11% FX headwind.","Q4 guidance: constant currency sales growth 6%-8%; non-GAAP EPS $3.66-$3.76."],"consensus_eps_estimate":null,"consensus_eps_actual":7.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":2113446000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":347090,"accession_number":"0001193125-22-209348","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2022-08-02T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Waters Q2 sales $714M +10% cc, GAAP EPS $2.72, non-GAAP $2.75; raises FY sales guidance to 9.5-10.5%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 sales $714M (+5% as reported, +10% constant currency); instrument sales +12% cc, recurring +8% cc.","GAAP EPS $2.72; non-GAAP EPS $2.75, up 6% YoY; includes ~11% FX headwind.","Full-year 2022 constant currency sales growth guidance raised to 9.5%-10.5%; non-GAAP EPS reaffirmed $11.95-$12.05.","Q3 guidance: constant currency sales growth 8%-10%; non-GAAP EPS $2.50-$2.60.","Director Thomas Salice retired from board effective July 28; board size reduced to seven."],"consensus_eps_estimate":null,"consensus_eps_actual":5.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":1404891000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363493,"accession_number":"0001193125-22-159800","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2022-05-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Waters shareholders re-elect all 8 directors, ratify PwC, approve say-on-pay at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 8 director nominees elected; votes ranged from 46.9M (Ornskov) to 53.2M (Jiang) in favor.","Ratification of PricewaterhouseCoopers as independent auditor for FY2022 approved with 51.8M for, 3.3M against.","Non-binding advisory vote on executive compensation passed with 46.8M for, 6.7M against.","Approximately 91% of shares entitled to vote were present or represented by proxy (55.2M shares)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363492,"accession_number":"0001193125-22-154540","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2022-05-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Waters holds 2022 Investor Day; reiterates prior guidance, no new financials","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Held Investor Day on May 19, 2022 at NYSE with live webcast; presentation covers historical performance, strategy, and outlook.","2022 guidance first disclosed May 3, 2022 is included for reference only; not updated or reaffirmed.","No new financial figures or guidance changes were announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363491,"accession_number":"0001193125-22-137552","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2022-05-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Waters reports Q1 2022 results; financial details not extractable from filing","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Filed results for quarter ended April 2, 2022 via press release Exhibit 99.1.","Press release text in filing excerpt is truncated; no revenue, EPS, or segment data visible.","Contact provided: Caspar Tudor, Director, 508-482-2401."],"consensus_eps_estimate":null,"consensus_eps_actual":2.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":690572000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363490,"accession_number":"0001193125-22-092984","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2022-04-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Waters director John Ballbach resigns from board effective March 30, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Ballbach resigned from the Waters Corporation Board of Directors on March 30, 2022.","The Company thanked Mr. Ballbach for his strategic and operational insights during his tenure.","No replacement director has been named as of the filing date.","The resignation is not related to any disagreement with the Company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":383292,"accession_number":"0001193125-22-023950","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2022-02-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Waters announces Q4 and full year 2021 results; details not available from provided filing text","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release referenced as Exhibit 99.1 but full text not included in filing excerpt.","No specific financial figures (revenue, EPS, guidance) can be extracted.","Filing dated February 1, 2022; results for period ended December 31, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":11.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":2785874000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":383291,"accession_number":"0001193125-22-005066","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2022-01-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Waters presents at J.P. Morgan Healthcare Conference, details not in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Investor presentation furnished as Exhibit 99.1 for J.P. Morgan Healthcare Conference on Jan 10, 2022.","Presentation includes high-level commentary on business performance, but full content was not included in the filing.","No specific financial data, guidance, or material updates were disclosed in this 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-01-10T23:59:59+00:00|383291"}